This is a prospective, multicenter study of luspatercept in RBC transfusion-dependent MDS patients with different categories of IPSS-R and IPSS-M
Latest Information Update: 30 Sep 2024
Price :
$35 *
At a glance
- Drugs Luspatercept (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 30 Sep 2024 New trial record